Peter Thiel-backed ATAI is preparing to go to Nasdaq, as interest in psychedelics reaches fever pitch
Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
